Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 23 (3), 170-9

Efficacy and Tolerability of Second-Generation Antidepressants in Social Anxiety Disorder

Affiliations
Review

Efficacy and Tolerability of Second-Generation Antidepressants in Social Anxiety Disorder

Richard A Hansen et al. Int Clin Psychopharmacol.

Abstract

A systematic review and meta-analysis were conducted to evaluate the comparative efficacy and tolerability of second-generation antidepressants in social anxiety disorder. Studies were identified by searching MEDLINE, Embase, The Cochrane Library, PsychLit, and the International Pharmaceutical Abstracts from January 1980 through October 2006. Comparative evidence was summarized and indirect comparisons were made using network meta-analysis. Only three head-to-head trials were identified; comparative trials found only minimal differences in efficacy between escitalopram and paroxetine, and no statistically significant differences in efficacy between extended-release venlafaxine and paroxetine. Pooled evidence from 15 placebo-controlled trials suggests that escitalopram [relative benefit (RB) 1.3; 95% confidence interval (CI) 1.2-1.5], paroxetine (RB 1.9; 95% CI 1.5-2.3), sertraline (RB 1.8; 95% CI 1.5-2.2), and venlafaxine (RB 1.7; 95% CI 1.5-1.9) all produce significantly more responders than placebo; evidence favored fluvoxamine over placebo but was not significant (RB 1.5; 95% CI 0.9-2.4). Network meta-analysis did not reveal differences in efficacy among drugs. Overall, a fair amount of evidence supports the efficacy of escitalopram, fluvoxamine, paroxetine, sertraline, and venlafaxine in social anxiety disorder. The drugs do not differ in efficacy, although their adverse event profiles do.

Figures

Figure 1
Figure 1
Liebowitz social anxiety scale meta-analysis (random effects)
Figure 2
Figure 2
Clinical global impression of improvement meta-analysis (random effects)
Figure 3
Figure 3
Indirect comparisons of second-generation antidepressants * Outcome defined as “much” or “very much” improved on the clinical global impression of improvement scale

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

MeSH terms

Substances

Feedback